Exercise programs with higher intensity levels result in better outcomes for patients
the ONA take:
A supervised, moderate- to high-intensity exercise program that combines resistance and aerobic exercise (eg, OnTrack) is most effective for patients with breast cancer undergoing adjuvant chemotherapy.
However, a home-based, low-intensity physical activity program (eg, Onco-Move) provides some benefit and is a viable alternative for women who cannot or will not participate in more intensive exercise compared with usual care (UC).
In this study, 230 women who were scheduled to undergo adjuvant chemotherapy were randomly assigned to Onco-Move, OnTrack, or (UC). Assessments were made before assignment, at the end of chemotherapy, and at the 6-month follow-up.
Cardiorespiratory fitness, physical functioning, nausea and vomiting, and pain outcomes were all better in the intervention groups compared with the UC group.
Those in the OnTrack group also had better muscle strength and less physical fatigue, plus a smaller percentage of them needed dose adjustments.
In addition, patients in both intervention groups returned earlier, as well as for more hours per week, to work than patients in the UC group.
A supervised, moderate- to high-intensity exercise program is most effective for patients with breast cancer undergoing adjuvant chemotherapy.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|